内容发布更新时间 : 2024/5/3 9:16:39星期一 下面是文章的全部内容请认真阅读。

[133] Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with

unresectable liver metastases from colorectal carcinoma. J Clin Oncol, 2005, 23: 2038-2048.

[134] Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy:

does it mean cure? J Clin Oncol, 2006, 24: 3939-3945.

[135] Gruenberger B, Scheithauer W, Punzengruber R, et al. Importance of response to neoadjuvant chemotherapy

in potentially curable colorectal cancer liver metastases. BMC Cancer, 2008, 8: 120.

[136] Chiappa A, Bertani E, Makuuchi M, et al. Neoadjuvant chemotherapy followed by hepatectomy for

primarily resectable colorectal cancer liver metastases. Hepatogastroenterology, 2009, 56: 829-834. [137] Abdalla EK, Adam R, Bilchik AJ, et al. Improving resectability of hepatic colorectal metastases: expert

consensus statement. Ann Surg Oncol, 2006, 13: 1271-1280.

[138] Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases:

correlation between tumour response and resection rates. Ann Oncol, 2005, 16: 1311-1319.

[139] Mentha G, Majno P, Terraz S, et al. Treatment strategies for the management of advanced colorectal liver

metastases detected synchronously with the primary tumour. Eur J Surg Oncol, 2007, 33 Suppl 2: S76-S83.

[140] Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus

surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 2008, 371: 1007-1016.

[141] Nordlinger B, Van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role

of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol, 2009, 20: 985-992.

[142] Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal

cancer patients treated with 5-?uorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg , 2009, 249: 420-425.

[143] Kataoka K, Kanazawa A, Nakajima A, et al. The feasibility and potential benefit of preoperative

chemotherapy for colorectal liver metastasis (CLM): a single-centered retrospective study. Surg Today, 2012, In press.

[144] Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy

with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol, 2006, 24: 4983-4990. [145] Malik HZ, Farid S, Al-Mukthar A, et al. A critical appraisal of the role of neoadjuvant chemotherapy for

colorectal liver metastases: a case-controlled study. Ann Surg Oncol, 2007, 14: 3519-3526. [146] Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal

metastases is a matter of timing. Br J Cancer, 2007, 96: 1037-1042.

[147] Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major

hepatectomy for colorectal liver metastases. Ann Surg, 2006, 243: 1-7.

[148] Kandutsch S, Klinger M, Hacker S, et al. Patterns of hepatotoxicity after chemotherapy for colorectal cancer

liver metastases. Eur J Surg Oncol, 2008, 34: 1231-1236.

[149] Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin

pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg, 2005, 200: 845-853. [150] Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in

90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol, 2006, 24: 2065-2072.

[151] Pawlik TM, Olino K, Gleisner AL, et al. Preoperative chemotherapy for colorectal liver metastases: impact

on hepatic histology and postoperative outcome. J Gastrointest Surg, 2007, 11: 860-868. [152] Gomez D, Malik HZ, Bonney GK, et al. Steatosis predicts postoperative morbidity following hepatic

resection for colorectal metastasis. Br J Surg, 2007, 94: 1395-1402.

[153] Nakano H, Oussultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in

patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg, 2008, 247: 118-124.

[154] McCormack L, Petrowsky H, Jochum W, et al. Hepatic steatosis is a risk factor for postoperative

complications after major hepatectomy: a matched case-control study. Ann Surg, 2007, 245: 923-930. [155] Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for

colorectal liver metastases: myth or reality? J Clin Oncol, 2008, 26: 1635-1641.

[156] van Vledder MG, de Jong MC, Pawlik TM, et al. Disappearing colorectal liver metastases after

chemotherapy: should we be concerned? J Gastrointest Surg, 2010, 14: 1691-1700.

[157] Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged

by chemotherapy: a model to predict long-term survival. Ann Surg, 2004, 240: 644-657.

[158] Benoist S, Nordlinger B. Neoadjuvant treatment before resection of liver metastases. Eur J Surg Oncol, 2007,

33 Suppl 2: S35-S41.

[159] Reddy SK, Barbas AS, Clary BM. Synchronous colorectal liver metastases: is it time to reconsider

traditional paradigms of management? Ann Surg Oncol, 2009 , 16: 2395-2410.

[160] Poultsides GA, Servais EL, Saltz LB, et al. Outcome of primary tumor in patients with synchronous stage IV

colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol, 2009, 27: 3379-3384.

[161] Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for

colorectal liver metastases. Eur J Surg Oncol, 2008, 34: 782-786.

[162] Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant

therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol, 2008, 26: 1830-1835. [163] Coskun U, Buyukberber S, Yaman E, et al. Xelox (capecitabine plus oxaliplatin) as neoadjuvant

chemotherapy of unresectable liver metastases in colorectal cancer patients. Neoplasma, 2008, 55: 65-70. [164] Cassidy J, Clarke s, Diaz-Rubio E, et al. XELOX vs. FOLFOX4: efficacy results from XELOX-1/NO16966,

a randomized phase III trial in first-line metastatic colorectal cancer(MCRC). 2007 Gastroimtestinal Cancers Symposium 2007, Abstract 270.

[165] Tan BR, Zubal B, Hawkins W, et al. Preoperative FOLFOX plus cetuximab or panitumumab therapy for

patients with potentially resectable hepatic colorectal metastases. Gastrointestinal Cancers Symposium, 2009, Abstract 497.

[166] Pessaux P, Marzano E, Casnedi S, et al. Histological and immediate postoperative outcome after

preoperative cetuximab: case-matched control study.World J Surg, 2010, 34: 2765-2772.

[167] Pessaux P, Panaro F, Casnedi S, et al. Targeted molecular therapies (cetuximab and bevacizumab) do not

induce additional hepatotoxicity: preliminary results of a case-control study. Eur J Surg Oncol, 2010, 36: 575-582.

[168] Okines A, Puerto OD, Cunningham D, et al. Surgery with curative-intent in patients treated with first-line

chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer, 2009, 101: 1033-1038.

[169] Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal

liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol, 2010, 11: 38-47.

[170] LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of

VEGFR-1. Science, 2003, 299: 890-893.

[171] Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic

colorectal cancer patients treated with bevacizumab. J Surg Oncol, 2005, 91: 173-180.

[172] Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era

of bevacizumab. J Clin Oncol, 2005, 23: 4853-4855.

[173] D’Angelica M, Kornprat P, Gonen M, et al. Lack of evidence for increased operative morbidity after

hepatectomy with perioperative use of bevacizumab: a matched case-control study. Ann Surg Oncol, 2007, 14: 759-765.

[174] Reddy SK, Morse MA, Hurwitz HI, et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based

preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg, 2008, 206: 96-106.

[175] De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to

early radiological response in metastastic colorectal cancer treated with cetuximab. Ann Oncol, 2008, 19: 508-515.

[176] Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced

colorectal cancer. N Engl J Med, 2008, 359: 1757-1765.

[177] Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients

with metastatic colorectal cancer. J Clin Oncol, 2008, 26: 1626-1634.

[178] Van Cutsem E, K?hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic

colorectal cancer. N Engl J Med, 2009, 360: 1408-1417.

[179] Bokemeyer C, Bandarenko I, Mahkson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without

cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2009, 27: 663-671 [180] Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with

hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol, 2005, 23: 4888- 4896.

[181] Kemeny N, Eid A, Stockman J, et al. Hepatic arterial infusion of ?oxuridine and dexamethasone plus

high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol, 2005, 91: 97-101.

[182] Clancy TE, Dixon E, Perlis R, et al. Hepatic arterial infusion after curative resection of colorectal cancer

metastases: a meta-analysis of prospective clinical trials. J Gastrointest Surg, 2005, 9: 198-206.

[183] Zorzi D, Kishi Y, Maru DM, et al. Effect of extended preoperative chemotherapy on pathologic response and

postoperative liver insufficiency after hepatic resection for colorectal liver metastases. J Clin Oncol, 2009, Abstract 295.

[184] Choti MA. Chemotherapy-associated hepatotoxicity: do we need to be concerned? Ann Surg Oncol, 2009,

16: 2391-2394.

[185] Benoist S, Nordlinger B. The role of preoperative chemotherapy in patients with resectable colorectal liver

metastases. Ann Surg Oncol, 2009, 16: 2385-2390.

[186] Vadeyar HJ. Current therapeutic options for colorectal liver metastases. Indian J Gastroenterol, 2007, 26:

26-29.

[187] Ychou M, Hohenberger W, Thezenas S, et al. Randomized phase III trial comparing infused

5-?uorouracil/folinic acid (LV5FU) versus LV5FU+ irinotecan (LV5FU+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC).(CPT-GMA-301). J Clin Oncol, 2008, 26: abstr LBA4013.

[188] Gruenberger T, Kaczirek K, Bergmann M, et al. Progression-free survival in a phase II study of perioperative

bevacizumab plus XELOX in patients with potentially curable metastatic colorectal cancer. J Clin Oncol, 2008, 26: abstr 4073.

[189] Bouganim N, Ang C, Kavan P, et al. Perioperative bevacizumab containing chemotherapy for colorectal

liver metastases. J Clin Oncol, 2008, 26: abstr 15073.

[190] Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous,

colorectal liver metastases? Ann Surg, 2010, 252: 774-787.

[191] Goéré D, Benhaim L, Bonnet S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in

patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg, 2013, 257: 114-120.

[192] House MG, Kemeny NE, G?nen M, et al. Comparison of adjuvant systemic chemotherapy with or without

hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg, 2011, 254: 851-856.

[193] Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion

and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol, 2011, 29: 884-889.

[194] Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of

metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol, 2008, 26: 4906-4911.

[195] Ychou M, Hohenberger W, Thezenas S, et al. A randomized phase III study comparing adjuvant

5-?uorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol, 2009, 20: 1964-1970.

[196] Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid

compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol, 2006, 24: 4976-4982.

[197] Power DG, Kemeny NE. Role of adjuvant therapy after resection of colorectal cancer liver metastases. J Clin

Oncol, 2010, 28: 2300-2309.

[198] Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

Ann Oncol, 2003, 14 Suppl 2: ii13-ii16.

[199] Goldberg RM, Sargent DJ, Morton RF, et al. Randomized controlled trial of reduced-dose bolus fluorouracil

plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with

previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol, 2006, 24: 3347-3353.

[200] Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in

advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22: 229-237. [201] Cals L, Rixe O, Francois E, et al. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil

associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Ann Oncol, 2004, 15: 1018-1024.

[202] Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and

irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol, 2007, 25: 1670-1676.

[203] Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine

regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol , 2008, 26: 3523-3529.

[204] Mahnken AH, Pereira PL, de Baère T. Interventional oncologic approaches to liver metastases. Radiology,

2013, 266: 407-430.

[205] Goéré D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer

patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg, 2010, 251: 686-691.

[206] Nishiofuku H, Tanaka T, Aramaki T, et al. Hepatic arterial infusion of 5-fluorouracil for patients with liver

metastases from colorectal cancer refractory to standard systemic chemotherapy: a multicenter, retrospective analysis. Clin Colorectal Cancer, 2010, 9: 305-310.

[207] Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in

first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol, 2005, 23: 3697-3705.

[208] Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy

as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 2008, 26: 2013-2019.

[209] Fraker DL, Soulen M. Regional therapy of hepatic metastases. Hematol Oncol Clin North Am, 2002, 16:

947-967.

[210] Nitzkorski JR, Farma JM, Watson JC, et al. Outcome and natural history of patients with stage IV colorectal

cancer receiving chemotherapy without primary tumor resection. Ann Surg Oncol, 2012, 19: 379-383. [211] Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an asymptomatic primary tumour

in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev, 2012, 8: CD008997. [212] Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the

treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell’Italia Meridionale. J Clin Oncol, 2005, 23: 4866-4875.

[213] Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in

predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol, 2007, 18: 299-304.